---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-23-000175"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2023-11-24T23:59:59+00:00"
generated_at: "2026-06-07T21:57:03.118910+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GRI Bio receives Nasdaq delisting notice for failing stockholders' equity requirement

## Summary
- Notice received Nov 22, 2023 for non-compliance with Nasdaq Listing Rule 5550(b)(1) requiring minimum $2.5M stockholders' equity.
- Stockholders' equity fell below $2.5M as of September 30, 2023 based on Q3 10-Q.
- Company must submit a compliance plan by January 6, 2024 to avoid potential delisting.
- If plan accepted, Nasdaq may grant up to 180 calendar days extension to regain compliance.
- No immediate effect on trading but risk of delisting if compliance plan is rejected.

## SEC filing metadata
- accession: 0001824293-23-000175
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2023-11-24T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429323000175/0001824293-23-000175-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429323000175/val-20231122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-23-000175
- JSON: https://secwatch.observer/filing/0001824293-23-000175.json
- Plain text: https://secwatch.observer/filing/0001824293-23-000175.txt

## Key facts
- Listing & Compliance Notices
  GRI Bio, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: November 22, 2023, GRI Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Notice”) based on the information provided in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. Nasdaq Listing Rule 5550(b)(1) requires that companies listed on The Nasdaq Capital Market with a market value of listed securities of less than
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824293/000182429323000175/0001824293-23-000175-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.